is a preclinical screening, efficacy, and safety, CRO with expertise in physio-pathological models, customized procedures, and tailored drug discovery and development solutions. We have an international reputation that has been nurtured over the last 35 years, servicing pharmaceutical and biotechnology companies, academic institutes, and not-for-profit organizations worldwide.
Our in vitro and in vivo capabilities span multiple disease areas, including the central nervous system, oncology, pain, inflammation, cardiac and vascular diseases, metabolic and eating disorders, dermatology, and medical devices.
We provide in vitro services in many cell lines and in vivo models in diverse species, including mouse, rat, guinea pig, rabbit, ferret, mini-pig and dog. This approach helps address evolving needs of the industry and the associated translational challenges.
Porsolt’s GLP compliant and AAALAC accredited laboratories are based in France, where we also perform GLP safety evaluation of drug candidates, comprising predictive toxicology, full assessment of Central Nervous System, Cardiac, and Respiratory risk, as well as Dug Abuse and Dependence Liability.
Clients confidently work with Porsolt at multiple points in the drug development process, from target identification, screening and proof of concept, all the way through efficacy and safety regulatory studies, prior to first-in-man administration.
We employ predictive tools, standardized, and innovative methods, including cell-based models, in vivo models, histological techniques and image analyses, ex-vivo capabilities, and chemistry and biomarker assessments, in order to optimize our client’s drug discovery pipelines.
Please contact us through our website www.porsolt.com
, or email firstname.lastname@example.org
, for additional information about our expertise and capabilities, or to schedule a meeting with our experienced staff.